Ian M. Silverman

Ian M. Silverman

Auto-generated profile, based on publicly available information

Ian M. Silverman

Repare Therapeutics, Cambridge, Massachusetts

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2016 in Cell Metabolism
Verified
Journal Article
Closed access
DFDavid W. Frederick
David W. Frederick
ELEmanuele Loro
Emanuele Loro
LLLing Liu
Ling Liu
ADAntonio Davila
Antonio Davila
KCKarthikeyani Chellappa
Karthikeyani Chellappa
JBJoseph A. Baur
Joseph A. Baur

1 February 2021 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
ISIan M. Silverman
Ian M. Silverman
AHAntoine Hollebecque
Antoine Hollebecque
LFLuc Friboulet
Luc Friboulet
SOSherry Owens
Sherry Owens
RNRobert C. Newton
Robert C. Newton
TBTimothy C. Burn
Timothy C. Burn
Pemigatinib, a selective FGFR1–3 inhibitor, has demonstrated antitumor activity in FIGHT-202, a phase II study in patients with cholangiocarcinoma harboring FGFR2 fusions/rearrangements, and has gained regulatory approval in the United States. Eligibility for FIGHT-202 was assessed using genomic profiling; here, these data were utilized to characterize the genomic landscape of cholangiocarcinoma and to uncover unique molecular features of patients harboring FGFR2 rearrangements. The results highlight the high percentage of patients with cholangiocarcinoma harboring potentially actionable genomic alterations and the diversity in gene partners that rearrange with FGFR2. Clinicogenomic analysis of pemigatinib-treated patients identified mechanisms of primary and acquired resistance. Genomic subsets of patients with other potentially actionable FGF/FGFR alterations were also identified. Our study provides a framework for molecularly guided clinical trials and underscores the importance of genomic profiling to enable a deeper understanding of the molecular basis for response and nonresponse to targeted therapy. Significance: We utilized genomic profiling data from FIGHT-202 to gain insights into the genomic landscape of cholangiocarcinoma, to understand the molecular diversity of patients with FGFR2 fusions or rearrangements, and to interrogate the clinicogenomics of patients treated with pemigatinib. Our study highlights the utility of genomic profiling in clinical trials. This article is highlighted in the In This Issue feature, p. 211

22 October 2013 in RNA
Verified
Journal Article
Open access
PDF file
PRPaul Ryvkin
Paul Ryvkin
YLYuk Yee Leung
Yuk Yee Leung
ISIan M. Silverman
Ian M. Silverman
MCMicah Childress
Micah Childress
OVOtto Valladares
Otto Valladares
LWLi-San Wang
Li-San Wang
RNA is often altered post-transcriptionally by the covalent modification of particular nucleotides; these modifications are known to modulate the structure and activity of their host RNAs. The recent discovery that an RNA methyl-6 adenosine demethylase (FTO) is a risk gene in obesity has brought to light the significance of RNA modifications to human biology. These noncanonical nucleotides, when converted to cDNA in the course of RNA sequencing, can produce sequence patterns that are distinguishable from simple base-calling errors. To determine whether these modifications can be detected in RNA sequencing data, we developed a method that can not only locate these modifications transcriptome-wide with single nucleotide resolution, but can also differentiate between different classes of modifications. Using small RNA-seq data we were able to detect 92% of all known human tRNA modification sites that are predicted to affect RT activity. We also found that different modifications produce distinct patterns of cDNA sequence, allowing us to differentiate between two classes of adenosine and two classes of guanine modifications with 98% and 79% accuracy, respectively. To show the robustness of this method to sample preparation and sequencing methods, as well as to organismal diversity, we applied it to a publicly available yeast data set and achieved similar levels of accuracy. We also experimentally validated two novel and one known 3-methylcytosine (3mC) sites predicted by HAMR in human tRNAs. Researchers can now use our method to identify and characterize RNA modifications using only RNA-seq data, both retrospectively and when asking questions specifically about modified RNA.

5 June 2023 in Nature Medicine
Verified
Journal Article
Open access
PDF file
TYTimothy A. Yap
Timothy A. Yap
EFElisa Fontana
Elisa Fontana
ELElizabeth Lee
Elizabeth Lee
DSDavid R. Spigel
David R. Spigel
MHMartin Højgaard
Martin Højgaard
EREzra Rosen
Ezra Rosen
Predictive biomarkers of response are essential to effectively guide targeted cancer treatment. Ataxia telangiectasia and Rad3-related kinase inhibitors (ATRi) have been shown to be synthetic lethal with loss of function (LOF) of ataxia telangiectasia-mutated (ATM) kinase, and preclinical studies have identified ATRi-sensitizing alterations in other DNA damage response (DDR) genes. Here we report the results from module 1 of an ongoing phase 1 trial of the ATRi camonsertib (RP-3500) in 120 patients with advanced solid tumors harboring LOF alterations in DDR genes, predicted by chemogenomic CRISPR screens to sensitize tumors to ATRi. Primary objectives were to determine safety and propose a recommended phase 2 dose (RP2D). Secondary objectives were to assess preliminary anti-tumor activity, to characterize camonsertib pharmacokinetics and relationship with pharmacodynamic biomarkers and to evaluate methods for detecting ATRi-sensitizing biomarkers. Camonsertib was well tolerated; anemia was the most common drug-related toxicity (32% grade 3). Preliminary RP2D was 160 mg weekly on days 1–3. Overall clinical response, clinical benefit and molecular response rates across tumor and molecular subtypes in patients who received biologically effective doses of camonsertib (>100 mg d−1) were 13% (13/99), 43% (43/99) and 43% (27/63), respectively. Clinical benefit was highest in ovarian cancer, in tumors with biallelic LOF alterations and in patients with molecular responses. ClinicalTrials.gov registration: NCT04497116.

24 November 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
Tareq A. JuratliTareq A. Juratli
Tareq A. Juratli
CTChristian Thiede
Christian Thiede
MKMara V.A. Koerner
Mara V.A. Koerner
STShilpa S. Tummala
Shilpa S. Tummala
DDDirk Daubner
Dirk Daubner
DCDaniel Cahill
Daniel Cahill
Intratumoral heterogeneity and TERT promoter mutations in progressive/higher-grade meningiomas Intratumoral heterogeneity and TERT promoter mutations in progressive/higher-grade meningiomas

1 January 2015 in Molecular Cell
Verified
Journal Article
Closed access
SGSager J. Gosai
Sager J. Gosai
SFShawn W. Foley
Shawn W. Foley
DWDongxue Wang
Dongxue Wang
ISIan M. Silverman
Ian M. Silverman
NSNur Selamoglu
Nur Selamoglu
BGBrian Gregory
Brian Gregory